Skip to main content
Top
Published in: Digestive Diseases and Sciences 5/2009

01-05-2009 | ORIGINAL ARTICLE

Does the Expression of Cyclin E, pRb, and p21 Correlate with Prognosis in Gastric Adenocarcinoma?

Authors: Gregory Kouraklis, Iraklis E. Katsoulis, Stamatios Theocharis, Gerasimos Tsourouflis, Nikos Xipolitas, Andromahi Glinavou, Chrysa Sioka, Alkiviadis Kostakis

Published in: Digestive Diseases and Sciences | Issue 5/2009

Login to get access

Abstract

Background Cyclin E is a protein that plays a key role in the G1 → S transition of the normal cell cycle. The product of retinoblastoma gene (pRb) is the master regulator of entry into the cell cycle and p21 protein is a cyclin-dependent kinase inhibitor that disturbs the progression through the cell cycle. The expression of these proteins, among many others, is being deregulated in tumorogenesis. The aim of this study was to investigate whether cyclin E, pRb, and p21 can be used as prognostic indicators in gastric cancer. Material and Methods Fifty-six patients with gastric adenocarcinoma, who underwent curative resection, constituted the group of our study. The immunohistochemical expression of cyclin E, pRb, and p21 proteins was examined and correlated with clinical-pathological parameters and survival. Results Positive cyclin E immunostaining was observed in 23 tumors (41.1%). It was associated with intestinal Lauren classification (P = 0.003), nodal infiltration (P = 0.0025), size of the tumor >5 cm (P = 0.032), and lymphatic (P = 0.042) and vascular invasion (P = 0.0029). Nevertheless, the survival of patients with positive cyclin E tumors was not significantly shorter than that of negative patients. Positive pRb immunostaining was found in 24 (42.9%) cases and it was associated with the absence of Helicobacter pylori (P = 0.044), whereas positive p21 immunostaining was found in 21 tumors (37.5%) and it was associated with less depth of gastric wall infiltration (P = 0.001), the absence of lymphatic (P = 0.019) and vascular infiltration (P = 0.024), and the absence of liver metastasis (P = 0.044). Cyclin E expression was associated with pRb expression (P = 0.023), but was correlated inversely with p21 expression (P = 0.009). The survival of patients with pRb-positive tumors and the survival of patients with p21-positive tumors were significantly longer than that of negative patients (P = 0.0044 and P < 0.001, respectively). Conclusion The expression of cyclin E could not predict the survival in this series of patients with gastric cancer, whereas the expression of pRb and p21 was associated with a favorable prognosis.
Literature
3.
go back to reference Puduvalli VK, Kyritsis AP, Hess KR, et al. Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival. Int J Oncol. 2000;17(5):963–969.PubMed Puduvalli VK, Kyritsis AP, Hess KR, et al. Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival. Int J Oncol. 2000;17(5):963–969.PubMed
4.
go back to reference Akama Y, Yasui W, Yokozaki H, et al. Frequent amplification of the cyclin E gene in gastric carcinoma. Jpn J Cancer Res. 1995;86:617–621.PubMed Akama Y, Yasui W, Yokozaki H, et al. Frequent amplification of the cyclin E gene in gastric carcinoma. Jpn J Cancer Res. 1995;86:617–621.PubMed
5.
go back to reference Yasui W, Akama Y, Kuniyasu H, et al. Expression of cyclin E in human gastric adenomas and adenocarcinomas: correlation with proliferative activity and p53 status. J Exp Ther Oncol. 1996;1:88–94.PubMed Yasui W, Akama Y, Kuniyasu H, et al. Expression of cyclin E in human gastric adenomas and adenocarcinomas: correlation with proliferative activity and p53 status. J Exp Ther Oncol. 1996;1:88–94.PubMed
6.
go back to reference Yasui W, Kudo Y, Semba S, Yokozaki H, Tahara E. Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res. 1997;88:625–629.PubMed Yasui W, Kudo Y, Semba S, Yokozaki H, Tahara E. Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res. 1997;88:625–629.PubMed
8.
go back to reference Jiaqing L, Hokita S, Xiangming C, et al. Role of cyclin E and p53 expression in progression of early gastric cancer. Gastric Cancer. 1998;1(2):160–165. doi:10.1007/s101200050011 Jiaqing L, Hokita S, Xiangming C, et al. Role of cyclin E and p53 expression in progression of early gastric cancer. Gastric Cancer. 1998;1(2):160–165. doi:10.​1007/​s101200050011
9.
go back to reference Sakaguchi T, Watanabe A, Sawada H, et al. Prognostic value of cyclin E and p53 expression in gastric carcinoma. Cancer. 1998;82(7):1238–1243. doi:10.1002/(SICI)1097-0142(19980401)82:7<1238::AID-CNCR5>3.0.CO;2-B Sakaguchi T, Watanabe A, Sawada H, et al. Prognostic value of cyclin E and p53 expression in gastric carcinoma. Cancer. 1998;82(7):1238–1243. doi:10.1002/(SICI)1097-0142(19980401)82:7<1238::AID-CNCR5>3.0.CO;2-B
10.
go back to reference Ahn MJ, Kim BH, Jang SJ, et al. Expression of cyclin D1 and cyclin E in human gastric carcinoma and its clinicopathologic significance. J Korean Med Sci. 1998;13(5):513–518.PubMed Ahn MJ, Kim BH, Jang SJ, et al. Expression of cyclin D1 and cyclin E in human gastric carcinoma and its clinicopathologic significance. J Korean Med Sci. 1998;13(5):513–518.PubMed
11.
go back to reference Jang SJ, Park YW, Park MH, et al. Expression of cell-cycle regulators, cyclin E and p21WAF1/CIP1, potential prognostic markers for gastric cancer. Eur J Surg Oncol. 1999;25(2):157–63. doi:10.1053/ejso.1998.0619 Jang SJ, Park YW, Park MH, et al. Expression of cell-cycle regulators, cyclin E and p21WAF1/CIP1, potential prognostic markers for gastric cancer. Eur J Surg Oncol. 1999;25(2):157–63. doi:10.​1053/​ejso.​1998.​0619
12.
go back to reference Aoyagi K, Koufuji K, Yano S, et al. Immunohistochemical study on the expression of cyclin D1 and E in gastric cancer. Kurume Med J. 2000;47(3):199–203.PubMed Aoyagi K, Koufuji K, Yano S, et al. Immunohistochemical study on the expression of cyclin D1 and E in gastric cancer. Kurume Med J. 2000;47(3):199–203.PubMed
13.
14.
go back to reference Tenderenda M. A study on the prognostic value of cyclins D1 and E expression levels in respectable gastric cancer and on some correlations between cyclins expression, histoclinical parameters and selected protein products of cell-cycle regulatory genes. J Exp Clin Cancer Res. 2005;24(3):405–414.PubMed Tenderenda M. A study on the prognostic value of cyclins D1 and E expression levels in respectable gastric cancer and on some correlations between cyclins expression, histoclinical parameters and selected protein products of cell-cycle regulatory genes. J Exp Clin Cancer Res. 2005;24(3):405–414.PubMed
15.
go back to reference Liang B, Wang S, Yang X, Ye Y, Yu Y, Cui Z. Expressions of cyclin E cyclin dependent kinase 2 and p57 (KIP2) in human gastric cancer. Chin Med J (Engl). 2003;116:20–23. Liang B, Wang S, Yang X, Ye Y, Yu Y, Cui Z. Expressions of cyclin E cyclin dependent kinase 2 and p57 (KIP2) in human gastric cancer. Chin Med J (Engl). 2003;116:20–23.
16.
go back to reference Takano Y, Kato Y, van Diest PJ, Masuda M, Mitomi H, Okayasu I. Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol. 2000;156:585–594.PubMed Takano Y, Kato Y, van Diest PJ, Masuda M, Mitomi H, Okayasu I. Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol. 2000;156:585–594.PubMed
17.
go back to reference Muller W, Noguchi T, Wirtz HC, Hommel G, Gabbert HE. Expression of cell-cycle regulatory proteins cyclin D1, cyclin E, and their inhibitor p21 WAF1/CIP1 in gastric cancer. J Pathol. 1999;189:186–193. doi:10.1002/(SICI)1096-9896(199910)189:2<186::AID-PATH418>3.0.CO;2-L.PubMedCrossRef Muller W, Noguchi T, Wirtz HC, Hommel G, Gabbert HE. Expression of cell-cycle regulatory proteins cyclin D1, cyclin E, and their inhibitor p21 WAF1/CIP1 in gastric cancer. J Pathol. 1999;189:186–193. doi:10.1002/(SICI)1096-9896(199910)189:2<186::AID-PATH418>3.0.CO;2-L.PubMedCrossRef
18.
go back to reference Kwon OJ, Kang HS, Suh JS, Chang MS, Jang JJ, Chung JK. The loss of p27 protein has an independent prognostic significance in gastric cancer. Anticancer Res. 1999;19:4215–4220.PubMed Kwon OJ, Kang HS, Suh JS, Chang MS, Jang JJ, Chung JK. The loss of p27 protein has an independent prognostic significance in gastric cancer. Anticancer Res. 1999;19:4215–4220.PubMed
21.
go back to reference Gomyo Y, Ikeda M, Osaki M, et al. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in survival of patients with advanced gastric carcinoma. Cancer (Phila). 1997;79:2067–2072. doi:10.1002/(SICI)1097-0142(19970601)79:11<2067::AID-CNCR3>3.0.CO;2-M.CrossRef Gomyo Y, Ikeda M, Osaki M, et al. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in survival of patients with advanced gastric carcinoma. Cancer (Phila). 1997;79:2067–2072. doi:10.1002/(SICI)1097-0142(19970601)79:11<2067::AID-CNCR3>3.0.CO;2-M.CrossRef
22.
go back to reference Ogawa M, Maeda K, Onoda N, Chung YS, Sowa M. Loss of p21WAF1/CIP1 expression correlates with disease progression in gastric carcinoma. Br J Cancer. 1997;75(11):1617–1620.PubMed Ogawa M, Maeda K, Onoda N, Chung YS, Sowa M. Loss of p21WAF1/CIP1 expression correlates with disease progression in gastric carcinoma. Br J Cancer. 1997;75(11):1617–1620.PubMed
23.
24.
go back to reference Baldus SE, Schneider PM, Monig SP, et al. p21/waf1/cip1 in gastric cancer: associations with histopathological subtypes, lymphonodal metastasis, prognosis and p53 status. Scand J Gastroenterol. 2001;36(9):975–980. doi:10.1080/003655201750305512. Baldus SE, Schneider PM, Monig SP, et al. p21/waf1/cip1 in gastric cancer: associations with histopathological subtypes, lymphonodal metastasis, prognosis and p53 status. Scand J Gastroenterol. 2001;36(9):975–980. doi:10.​1080/​0036552017503055​12.
25.
go back to reference Okuyama T, Maehara Y, Kabashima A, Takahashi I, Kakeji Y, Sugimachi K. Combined evaluation of expressions of p53 and p21 proteins as prognostic factors for patients with gastric carcinoma. Oncology. 2002;63(4):353–361. doi:10.1159/000066223. Okuyama T, Maehara Y, Kabashima A, Takahashi I, Kakeji Y, Sugimachi K. Combined evaluation of expressions of p53 and p21 proteins as prognostic factors for patients with gastric carcinoma. Oncology. 2002;63(4):353–361. doi:10.​1159/​000066223.
26.
go back to reference Kaye PV, Radebold K, Isaacs S, Dent DM. Expression of p53 and p21waf1/cip1 in gastric carcinoma: lack of inter-relationship or correlation with prognosis. Eur J Surg Oncol. 2000;26(1):39–43. doi:10.1053/ejso.1999.0738. Kaye PV, Radebold K, Isaacs S, Dent DM. Expression of p53 and p21waf1/cip1 in gastric carcinoma: lack of inter-relationship or correlation with prognosis. Eur J Surg Oncol. 2000;26(1):39–43. doi:10.​1053/​ejso.​1999.​0738.
27.
go back to reference Feakins RM, Nickols CD, Bidd H, Walton SJ. Abnormal expression of pRb, p16, and cyclin D1 in gastric adenocarcinoma and its lymph node metastases: relationship with pathological features and survival. Hum Pathol. 2003;34(12):1276–1282. doi:10.1016/j.humpath.2003.07.005. Feakins RM, Nickols CD, Bidd H, Walton SJ. Abnormal expression of pRb, p16, and cyclin D1 in gastric adenocarcinoma and its lymph node metastases: relationship with pathological features and survival. Hum Pathol. 2003;34(12):1276–1282. doi:10.​1016/​j.​humpath.​2003.​07.​005.
28.
go back to reference Song HS, Kim IH, Sohn SS, Kwon KY, Lee WS. Prognostic significance of immunohistochemical expression of p53 and retinoblastoma gene protein (pRB) in curatively resected gastric cancer. Korean J Intern Med. 2005;20(1):1–7.PubMedCrossRef Song HS, Kim IH, Sohn SS, Kwon KY, Lee WS. Prognostic significance of immunohistochemical expression of p53 and retinoblastoma gene protein (pRB) in curatively resected gastric cancer. Korean J Intern Med. 2005;20(1):1–7.PubMedCrossRef
Metadata
Title
Does the Expression of Cyclin E, pRb, and p21 Correlate with Prognosis in Gastric Adenocarcinoma?
Authors
Gregory Kouraklis
Iraklis E. Katsoulis
Stamatios Theocharis
Gerasimos Tsourouflis
Nikos Xipolitas
Andromahi Glinavou
Chrysa Sioka
Alkiviadis Kostakis
Publication date
01-05-2009
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 5/2009
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-008-0464-y

Other articles of this Issue 5/2009

Digestive Diseases and Sciences 5/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.